View more on these topics

Regulator admits stakeholder may squeeze out IFAs

IFAs may be squeezed out of selling stakeholder as further consolidation results in increasingly remote distribution channels, admits the FSA.

In its Women and Personal Finance report published last week, the regulator says the 1 per cent cap will mean firms “will find it difficult to maintain expensive distribution structures such as company representatives and IFAs”.

It says consolidation will lead to a “much smaller number of much larger providers” which could lead to a lack of choice and access.

The report was prepared by FSA consumer division director Christine Farnish with industry representatives. It says stakeholder&#39s target audience and women value face-to-face contact with advisers but increased remote distribution could deny them access. Women are more likely to see an IFA than men but only 22 per cent of women have a pension compared with 40 per cent of men.

The report says: “It may be those companies with access to large customer bases that are best placed to benefit.

“The growth of plcs may lead to more cherrypicking of high-net-worth customers just at the time when products such as stakeholder are targeted at the mass market.”

Aifa director general Paul Smee says: “I think the FSA should be careful of entering this territory. I hope this is not what they are regulating for.”

Holden Meehan director Richard Hunter says: “I am glad to see the FSA focusing on these problems but this is closing the stable door after the horse has bolted.”


NU is sticking with tradition on with-profits

Other providers are offering stakeholder with-profits products but NU will crosssubsidise its bonus rate, presently 5.75 per cent, from its existing fund.The prospect of one group of policyholders potentially subsidising another is not problematic for NU, which says the likelihood of the guarantees being called upon is slim.DSS ringfencing rules mean traditional with-profits policyholders will […]

Pharmaceuticals are the future for iShares

Pharmaceuticals are the right medicine for iShares as it brings in the iBloomberg European pharmaceuticals fund.European pharmaceuticals is an exchange traded fund aimed at experienced investors looking for growth.The fund will track the Bloomberg European pharmaceutical index. This consists of 29 companies which include Glaxosmithkline, Merck, Roche Holdings, Astrazeneca and Novartis.This is the seventh exchange […]

Collins Stewart continues push for hedge funds

Collins Stewart’s range of Guernsey-based Hirzel House funds is growing with the introduction of the absolute return fund.A multi-manager fund of hedge funds, the absolute return fund is aimed at conservative investors who are new to the world of hedge funds, looking for a product that offers average returns for medium risk.The aim of the […]

Disclosure deluge

There has never been a more competitive time in the mortgage market. Borrowers are enjoying low interest rates. The big lenders have been sharpening their pencils and some have been cutting rates until it hurts. This is driven by massive competition within the market, with new entrants and incumbents fighting for a bigger share of […]


News and expert analysis straight to your inbox

Sign up


    Leave a comment


    Why register with Money Marketing ?

    Providing trusted insight for professional advisers. Since 1985 Money Marketing has helped promote and analyse the financial adviser community in the UK and continues to be the trusted industry brand for independent insight and thought leadership.

    News & analysis delivered directly to your inbox
    Register today to receive our range of news alerts including daily and weekly briefings

    Money Marketing Events
    Be the first to hear about our industry leading conferences, awards, roundtables and more.

    Research and insight
    Take part in and see the results of Money Marketing's flagship investigations into industry trends.

    Have your say
    Only registered users can post comments. As the voice of the adviser community, our content generates robust debate. Sign up today and make your voice heard.

    Register now

    Having problems?

    Contact us on +44 (0)20 7292 3712

    Lines are open Monday to Friday 9:00am -5.00pm